Sutton Lesley-Ann, Young Emma, Baliakas Panagiotis, Hadzidimitriou Anastasia, Moysiadis Theodoros, Plevova Karla, Rossi Davide, Kminkova Jana, Stalika Evangelia, Pedersen Lone Bredo, Malcikova Jitka, Agathangelidis Andreas, Davis Zadie, Mansouri Larry, Scarfò Lydia, Boudjoghra Myriam, Navarro Alba, Muggen Alice F, Yan Xiao-Jie, Nguyen-Khac Florence, Larrayoz Marta, Panagiotidis Panagiotis, Chiorazzi Nicholas, Niemann Carsten Utoft, Belessi Chrysoula, Campo Elias, Strefford Jonathan C, Langerak Anton W, Oscier David, Gaidano Gianluca, Pospisilova Sarka, Davi Frederic, Ghia Paolo, Stamatopoulos Kostas, Rosenquist Richard
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
Haematologica. 2016 Aug;101(8):959-67. doi: 10.3324/haematol.2016.141812. Epub 2016 May 19.
We report on markedly different frequencies of genetic lesions within subsets of chronic lymphocytic leukemia patients carrying mutated or unmutated stereotyped B-cell receptor immunoglobulins in the largest cohort (n=565) studied for this purpose. By combining data on recurrent gene mutations (BIRC3, MYD88, NOTCH1, SF3B1 and TP53) and cytogenetic aberrations, we reveal a subset-biased acquisition of gene mutations. More specifically, the frequency of NOTCH1 mutations was found to be enriched in subsets expressing unmutated immunoglobulin genes, i.e. #1, #6, #8 and #59 (22-34%), often in association with trisomy 12, and was significantly different (P<0.001) to the frequency observed in subset #2 (4%, aggressive disease, variable somatic hypermutation status) and subset #4 (1%, indolent disease, mutated immunoglobulin genes). Interestingly, subsets harboring a high frequency of NOTCH1 mutations were found to carry few (if any) SF3B1 mutations. This starkly contrasts with subsets #2 and #3 where, despite their immunogenetic differences, SF3B1 mutations occurred in 45% and 46% of cases, respectively. In addition, mutations within TP53, whilst enriched in subset #1 (16%), were rare in subsets #2 and #8 (both 2%), despite all being clinically aggressive. All subsets were negative for MYD88 mutations, whereas BIRC3 mutations were infrequent. Collectively, this striking bias and skewed distribution of mutations and cytogenetic aberrations within specific chronic lymphocytic leukemia subsets implies that the mechanisms underlying clinical aggressiveness are not uniform, but rather support the existence of distinct genetic pathways of clonal evolution governed by a particular stereotyped B-cell receptor selecting a certain molecular lesion(s).
我们报告了在为此目的研究的最大队列(n = 565)中,携带突变或未突变的定型B细胞受体免疫球蛋白的慢性淋巴细胞白血病患者亚组内遗传损伤频率的显著差异。通过结合复发性基因突变(BIRC3、MYD88、NOTCH1、SF3B1和TP53)和细胞遗传学异常的数据,我们揭示了基因突变的亚组偏向性获得。更具体地说,发现NOTCH1突变频率在表达未突变免疫球蛋白基因的亚组中富集,即#1、#6、#8和#59(22 - 34%),通常与12号染色体三体相关,并且与在亚组#2(4%,侵袭性疾病,体细胞超突变状态可变)和亚组#4(1%,惰性疾病,突变免疫球蛋白基因)中观察到的频率显著不同(P < 0.001)。有趣的是,发现携带高频率NOTCH1突变的亚组几乎没有(如果有的话)SF3B1突变。这与亚组#2和#3形成鲜明对比,尽管它们存在免疫遗传学差异,但SF3B1突变分别发生在45%和46%的病例中。此外,TP53内的突变虽然在亚组#1中富集(16%),但在亚组#2和#8中很少见(均为2%),尽管所有这些亚组在临床上都具有侵袭性。所有亚组的MYD88突变均为阴性,而BIRC3突变很少见。总体而言,特定慢性淋巴细胞白血病亚组内突变和细胞遗传学异常的这种显著偏向和分布不均意味着临床侵袭性的潜在机制并不统一,而是支持存在由特定定型B细胞受体选择特定分子损伤所控制的独特克隆进化遗传途径。